Stock Market Reviews

ICCM (IceCure Medical Ltd) News

Get the latest news, insights, and market updates on ICCM (IceCure Medical Ltd). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
  The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients with early-stage low risk breast cancer when combined with adjuvant endocrine therapy for women aged 70 and over, an estimated population of 46,000 women annually in the U.S. The announcement was made on October 3, 2025, by IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), the developer of minimally invasive c
  Oct 3, 2025 - $ICCM
• IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
  IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced its participation at the European Society of Breast Imaging ("EUSOBI") Congress 2025 in Aberdeen, United Kingdom, on September 25-27, 2025.
  Sep 30, 2025 - $ICCM
• IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
  IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced its participation at the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Annual Meeting on September 13-17, 2025, in Barcelona, Spain. The Company hosted a large number of medical practitioners interested in ProSense® at its booth. Booth visitors e
  Sep 22, 2025 - $ICCM
• IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
  IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent titled "Cryoprobe".
  Sep 18, 2025 - $ICCM
• IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications
  IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has received regulatory approval from the Medical Device Division of Israel's Ministry of Health ("AMAR") for its next-generation single cryoprobe cryoablation system, the XSense™ System and CryoProbes.
  Sep 15, 2025 - $ICCM
• Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate
  IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced two publications reporting positive results for the ProSense® cryoablation system in breast cancer stemming from the THERMAC Trial, an independent study taking place in the Netherlands which compares different methods of thermal ablation used for early-stage breast canc
  Sep 8, 2025 - $ICCM
• IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy
  IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced encouraging findings from a recently published, independently conducted study evaluating the efficacy and safety of personalized percutaneous single-probe liquid-nitrogen cryoablation with ProSense® in treating symptomatic abdominal wall endometriosis ("AWE").
  Sep 4, 2025 - $ICCM
• IceCure Medical Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
  NasdaqCM:ICCM 1 Year Share Price vs Fair Value Explore IceCure Medical's Fair Values from the Community and select...
  Aug 15, 2025 - $ICCM
• Icecure Medical Ltd (ICCM) (H1 2025) Earnings Call Highlights: Navigating Challenges and ...
  Despite revenue declines, Icecure Medical Ltd (ICCM) remains optimistic about FDA approval and European market expansion.
  Aug 14, 2025 - $ICCM
• IceCure Medical Ltd. (ICCM) Q2 Earnings Surpass Estimates
  IceCure Medical (ICCM) delivered earnings and revenue surprises of +200.00% and -34.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 13, 2025 - $ICCM